Table 1. Baseline characteristics by treatment group.
| CsAM (N = 191) | TacM (N = 167) | P value | |
|---|---|---|---|
| Male, n (%) | 105 (55.0) | 91 (54.5) | 0.93 |
| Age, years ± SD | 50.37 ± 13.7 | 50.5 ± 13.5 | 0.70 |
| Caucasian n (%) | 174 (94.1) | 149 (90.9) | 0.26 |
| HLA mismatch AB, mean ± SD | 1.69 ± 1.07 | 1.93 ± 1.23 | 0.29 |
| HLA mismatch DR, mean ± SD | 0.74 ± 0.64 | 0.90 ± 0.66 | 0.17 |
| Induction, n (%) | 0.87 | ||
| ATG | 2 (1.1) | 1 (0.6) | |
| Basiliximab | 185 (97.4) | 161 (98.2) | |
| Other | 3 (1.6) | 2 (1.2) | |
| Primary disease, n (%) | 0.005 | ||
| Primary glomerular disease/glomerulonephritis | 57 (29.8) | 43 (25.7) | |
| Cystic kidney disease | 35 (18.3) | 24 (14.4) | |
| Renovascular disease/ hypertension | 20 (10.5) | 20 (12) | |
| Diabetic nephropathy | 19 (9.9) | 11 (6.6) | |
| Tubulo-interstitial nephritis | 5 (2.6) | 0 (0) | |
| Urological complications | 11 (5.8) | 3 (1.8) | |
| Other | 44 (23) | 66 (39.5) | |
| First transplantation, n (%) | 160 (83.8) | 141 (84.4) | 0.86 |
| Donor characteristics | |||
| Male, n (%) | 90 (47.1) | 87 (52.1) | 0.35 |
| Age, years ± SD | 51.3 ± 12.0 | 49.8 ± 13.5 | 0.06 |
| Type of transplantation, n (%) | 0.07 | ||
| Living | 85 (44.5) | 87 (52.1) | |
| Donation after brain death | 71 (37.2) | 43 (25.7) | |
| Donation after cardiac death | 35 (18.3) | 37 (22.2) | |
| Cold ischemia time, deceased donors only, min ± S.D. | 478.7 ± 502.5 | 409.1 ± 457.5 | 0.04 |
| Delayed Graft function,n (%) | 44 (23.0) | 41 (24.6) | 0.74 |
Chi-squared test was used for the donor and recipient baseline characteristics. CsA: cyclosporine A with or without prednisone and MPS or MMF, Tac: tacrolimus with or without prednisone and MPS or MMF.